

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name <u>Elan Pharmaceutical Research Corporation</u>			
2. Address <input type="checkbox"/> Check if different than previously reported <u>1140 Connecticut Ave. NW Suite 350 Washington, DC 20036</u>			
3. Principal Place of Business (if different from line 2) City: <u>Gainesville</u> State/Zip (or Country) <u>GA 30504</u>			
4. Contact Name <u>Dennis L. Myers</u>	Telephone <u>(202) 872-7800</u>	E-mail (optional)	5. Senate ID # <u>5509612</u>
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # <u>35113000</u>

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇔ Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇔ \$ _____ <small>Income (nearest \$20,000)</small></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input checked="" type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇔ \$ _____ <small>Expenses (nearest \$20,000)</small></p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature _____

Printed Name and Title _____

LD-2 (REV. 6/98)

PAGE 1 of 2

Registrant Name Elan Pharmaceutical Research Corp. Client Name Same

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

Gene Patents

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
Commerce Committee
Intellectual Property Subcommittee

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Philip M. Budashewitz</u>		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Elan Corporation, plc is an affiliate of the registrant/client and would be adversely affected if gene patent laws are significantly altered.

Signature Dennis J. Myers Date 2/13/01

Printed Name and Title Dennis J. Myers Director, Regulatory Information